2986-19-8

Basic information

• Product Name: 2-METHYL-2-THIOPSEUDOUREA SULFATE
• Synonyms: 2-METHYL-2-THIOPSEUDOUREA,HEMISULFATE;2-METHYL-2-THIOPSEUDOUREA HEMISULFATE SALT;METHYL CARBAMIMIDOTHIOATE, HEMISULFATE;METHYL-ISO-THIOUREA;METHYLISOTHIOUREA SULFATE;S-METHYL ISOTHIOUREA (HEMISULFATE);S-METHYLISOTHIOUREA HEMISULFATE SALT;S-METHYLISOTHIOUREA SULFATE SALT
• CAS NO: 2986-19-8
• Molecular Formula: C₂H₆N₂S
• Molecular Weight: 278.37
• EINECS: 212-759-7
• Mol File: 2986-19-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: 240-241 °C (dec.)(lit.)
• Boiling Point: 138.8 °C at 760 mmHg
• Flash Point: 37.7 °C
• Appearance: /
• Density: 1.26 g/cm³
• Vapor Pressure: 6.62mmHg at 25°C
• Solubility: H2O: 0.1 g/mL, clear, colorless
• PKA: 9.66±0.40(Predicted)
• CAS DataBase Reference: 2-METHYL-2-THIOPSEUDOUREA SULFATE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHYL-2-THIOPSEUDOUREA SULFATE(2986-19-8)
• EPA Substance Registry System: 2-METHYL-2-THIOPSEUDOUREA SULFATE(2986-19-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 22-24/25
• RIDADR: 2811
• WGK Germany: 3
• RTECS: UM9200000
• Hazardous Substances Data: 2986-19-8(Hazardous Substances Data)

Usage

General Description

2-Methyl-2-thiopseudourea sulfate is a chemical compound with potential pharmaceutical applications. It is a derivative of thiopseudourea, a class of compounds known for their antiviral, antibacterial, and anticancer properties. This specific compound has been studied for its potential use in the treatment of herpes simplex virus and human cytomegalovirus infections. It is believed to inhibit viral replication by interfering with the function of viral DNA polymerases. Research on 2-methyl-2-thiopseudourea sulfate is ongoing, and it holds promise for the development of new antiviral drugs.

InChI:InChI=1/C2H6N2S.BrH/c1-5-2(3)4;/h1H3,(H3,3,4);1H

Upstream product

• 64-17-5 ethanol 
• 17356-08-0 thiourea 
• 74-88-4 methyl iodide 
• 62-56-6 thiourea 
• 77-78-1 dimethyl sulfate 
• 89483-81-8 1-[(6-methyl 1,4-benzodioxan-2 yl)methyl]4-aminomethyl piperidine 
• 10191-60-3 dimethyl N-cyanodithioiminocarbonate 
• 66356-40-9 N-Acetyl-S-methylisothiourea 
• 7732-18-5 water 
• 41208-11-1 1-isopropylidene-3-methylthioisosemicarbazide 
• 79-22-1 methyl chloroformate 
• 74-93-1 methylthiol 
• 420-04-2 CYANAMID 
• 60-29-7 diethyl ether 

Downstream Products

• 128452-38-0 2-(4-Methylsulfanyl-6-phenyl-[1,3,5]triazin-2-yl)-phenol 
• 389827-10-5 5-benzoyl-4-phenyl-2-methylthio-1H-pyrimidine 
• 910114-63-5 methyl N-({[(4-fluorobenzen-1-yl)methyl]amino}carbonyl)carbamimidothioate 
• 1207759-77-0 [2-(1-adamantyl)tetrazol-5-yl](3-amino-1,2,4-triazol-5-yl)methane 
• 173998-77-1 N-(tert-butyloxycarbonyl)-S-methylisothiourea 
• 4705-39-9 piperidine-1-carboxamidine 
• 17238-66-3 morpholine-4-carboxamidine 
• 18240-93-2 1,1-diethylguanidine 
• 89639-37-2 6-(chloromethyl)-2-(methylthio)pyrimidin-4-ol 
• 1671-08-5 5-Methoxy-2-methylthiopyrimidin-4(3H)-one 
• 325820-32-4 2-Methoxybenzylcarbonyl-S-methyl-2-thiopseudobiuret 
• 53554-29-3 ethyl 4-hydroxy-2-(methylthio)pyrimidine-5-carboxylate 
• 150807-99-1 3,4-dihydro-2,6-dimethylmercapto-4-oxopyrimidine-5-carbonitrile 
• 57-00-1 Creatinine 

Relevant articles and documents

Selenium-containing compounds and their use in treatment of neuro-degenerative diseases

The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, solvates or pro-drugs thereof. The invention also relates to a preparation method of the compound or the pharmaceutically acceptable salt, solvate or prodrug thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt, solvate or prodrug thereof and application ofthe compound or the pharmaceutically acceptable salt, solvate or prodrug thereof in preparation of drugs. The drugs are used for treating neuro-degenerative diseases.

Structure-Activity Relationship of Hetarylpropylguanidines Aiming at the Development of Selective Histamine Receptor Ligands?

New classes of alkylated hetarylpropylguanidines with different functionality and variation in spacer length were synthesized to determine their behavior at the four histamine receptor (H1R, H2R, H3R, H4R) subtypes. Alkylated guanidines with different terminal functional groups and varied basicity, like amine, guanidine and urea were developed, based on the lead structure SK&F 91486 (2). Furthermore, heteroatomic exchange at the guanidine structure of 2 led to simple analogues of the lead compound. Radioassays at all histamine receptor subtypes were accomplished, as well as organ bath studies at the guinea pig (gp) ileum (gpH1R) and right atrium (gpH2R). Ligands with terminal functionalization led to, partially, highly affine and potent structures (two digit nanomolar), which showed up a bad selectivity profile within the histamine receptor family. While the benzoylurea derivative 144 demonstrated a preference towards the human (h) H3R, S-methylisothiourea analogue 143 obtained high affinity at the hH4R (pKi=8.14) with moderate selectivity. The molecular basis of the latter finding was supported by computational studies.

Synthesis and cytotoxic activity of 2,5-disubstituted pyrimido[5,4-c] quinoline derivatives

A series of 2,5-disubstituted pyrimido[5,4-c]quinoline derivatives were synthesized and their cytotoxic activity against H460, HT-29 and MDA-MB-231 cell lines was evaluated in vitro. It was found that most of the tested compounds especially compound 17, s